<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PRANDIMET- repaglinide and metformin hydrochloride tablet </strong><br>Novo Nordisk<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use PrandiMet safely and effectively.<br>See full prescribing information for PrandiMet.<br>PrandiMet<span class="Sup">®</span> (repaglinide and metformin HCl) Tablets<br>Initial U.S. Approval: 2008</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span></span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning</span></span></h1>
<ul>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> can occur due to metformin accumulation. The risk increases with conditions such as <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, excess alcohol intake, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and acute <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. (<a href="#i4i_section_id_14e0b124-f6b0-4755-b467-9dff94d37911">5.1</a>)</span></li>
<li>
<span class="Bold">Symptoms include <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span></span><span class="Bold">, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, increasing <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and nonspecific <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal distress</span>. Laboratory abnormalities include low pH, increased <span class="product-label-link" type="condition" conceptid="4009397" conceptname="Anion gap">anion gap</span> and elevated blood lactate. (<a href="#i4i_section_id_14e0b124-f6b0-4755-b467-9dff94d37911">5.1</a>)</span>
</li>
<li>
<span class="Bold">If <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> is suspected, discontinue </span><span class="Bold">PrandiMet</span><span class="Bold"> and hospitalize the patient immediately.</span>
</li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><ul><li>Warnings and Precautions, Drug Interactions <a href="#i4i_section_id_fee49ddf-0ace-4b4e-95cf-eccaa63d3c4b">(5.7)</a> 3/2012</li></ul></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span></span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning</span></span></h1>
<ul>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> can occur due to metformin accumulation. The risk increases with conditions such as <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, excess alcohol intake, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and acute <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. (<a href="#i4i_section_id_14e0b124-f6b0-4755-b467-9dff94d37911">5.1</a>)</span></li>
<li>
<span class="Bold">Symptoms include <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span></span><span class="Bold">, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, increasing <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and nonspecific <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal distress</span>. Laboratory abnormalities include low pH, increased <span class="product-label-link" type="condition" conceptid="4009397" conceptname="Anion gap">anion gap</span> and elevated blood lactate. (<a href="#i4i_section_id_14e0b124-f6b0-4755-b467-9dff94d37911">5.1</a>)</span>
</li>
<li>
<span class="Bold">If <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> is suspected, discontinue </span><span class="Bold">PrandiMet</span><span class="Bold"> and hospitalize the patient immediately.</span>
</li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<ul><li>PrandiMet is a meglitinide and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus who are already treated with a meglitinide and metformin HCl or who have inadequate glycemic control on a meglitinide alone or metformin HCl alone. <a href="#i4i_indications_id_76496ea5-4e88-456c-9481-c65aacf7de27">(1)</a><p class="Highlighta"><span class="Underline">Important Limitations of Use:</span> </p>
</li></ul>
<ul><li>Do not use to treat type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>. <a href="#i4i_indications_id_76496ea5-4e88-456c-9481-c65aacf7de27">(1)</a>
</li></ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>The dosage of PrandiMet should be individualized. <a href="#i4i_dosage_admin_id_8c486c4c-6492-4d80-9147-d1ed763548a0">(2)</a>
</li>
<li>Start with 1 mg/500 mg twice daily unless the patient is already taking higher co-administered doses of repaglinide and metformin HCl. <a href="#i4i_dosage_admin_id_8c486c4c-6492-4d80-9147-d1ed763548a0">(2)</a>
</li>
<li>Do not exceed 10 mg repaglinide/2500 mg metformin HCl daily or 4 mg repaglinide/1000 mg metformin HCl per meal. <a href="#i4i_dosage_admin_id_8c486c4c-6492-4d80-9147-d1ed763548a0">(2)</a>
</li>
<li>Give in divided doses within 15 minutes prior to meals. <a href="#i4i_dosage_admin_id_8c486c4c-6492-4d80-9147-d1ed763548a0">(2)</a>
</li>
<li>Patients who skip a meal should skip the PrandiMet dose for that meal. <a href="#i4i_dosage_admin_id_8c486c4c-6492-4d80-9147-d1ed763548a0">(2)</a>
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">Tablets: </p>
<ul>
<li>1 mg repaglinide/500 mg metformin HCl <a href="#i4i_dosage_form_strength_id_838b2f4e-fa40-41ca-b922-8650993db636">(3)</a>
</li>
<li>2 mg repaglinide/500 mg metformin HCl <a href="#i4i_dosage_form_strength_id_838b2f4e-fa40-41ca-b922-8650993db636">(3)</a>
</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<p class="Highlighta">Do not use in patients: </p>
<ul>
<li>with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (<a href="#i4i_contraindications_id_762b4592-ea74-4134-b6f9-c6a51d185e23">4</a>, <a href="#i4i_section_id_2a30a5f3-e661-46b1-869b-e1f487223b03">5.2</a>)</li>
<li>with <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, including <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>. (<a href="#i4i_contraindications_id_762b4592-ea74-4134-b6f9-c6a51d185e23">4</a>, <a href="#i4i_section_id_14e0b124-f6b0-4755-b467-9dff94d37911">5.1</a>)</li>
<li>receiving gemfibrozil. (<a href="#i4i_contraindications_id_762b4592-ea74-4134-b6f9-c6a51d185e23">4</a>, <a href="#i4i_section_id_fee49ddf-0ace-4b4e-95cf-eccaa63d3c4b">5.7</a>, <a href="#i4i_section_id_8dda359b-a02f-42e1-9da8-532ad7523efd">7.2</a>, <a href="#i4i_pharmacokinetics_id_abd94ac1-a1c5-446a-9b45-8399b7204620">12.3</a>) </li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Metformin HCl is contraindicated in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Assess renal function before initiating PrandiMet and at least annually thereafter, and verify as normal. (<a href="#i4i_contraindications_id_762b4592-ea74-4134-b6f9-c6a51d185e23">4</a>, <a href="#i4i_section_id_2a30a5f3-e661-46b1-869b-e1f487223b03">5.2</a>)</li>
<li>Temporarily discontinue PrandiMet in patients receiving iodinated contrast for radiological studies. (<a href="#i4i_section_id_9dc1dd78-4eda-4c48-a45c-57e89d1b6f45">5.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span> is associated with <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. Recommend not using in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (<a href="#i4i_section_id_1400adc2-3342-429c-b074-b25eb7e02708">5.4</a>)</li>
<li>Alcohol potentiates the effect of metformin on lactate metabolism. Warn patients against excess alcohol intake. (<a href="#i4i_section_id_2d11e1db-a3f9-43c1-8e3b-773335a6c486">5.5</a>)</li>
<li>PrandiMet should not be used in combination with NPH insulin. (<a href="#i4i_section_id_baba9f2e-cbee-46b5-b168-e8b511332962">5.6</a>)</li>
<li>Gemfibrozil substantially increases repaglinide exposure. Coadministration of gemfibrozil and PrandiMet is not recommended. (<a href="#i4i_contraindications_id_762b4592-ea74-4134-b6f9-c6a51d185e23">4</a>, <a href="#i4i_section_id_fee49ddf-0ace-4b4e-95cf-eccaa63d3c4b">5.7</a>, <a href="#i4i_section_id_8dda359b-a02f-42e1-9da8-532ad7523efd">7.2</a>, <a href="#i4i_pharmacokinetics_id_abd94ac1-a1c5-446a-9b45-8399b7204620">12.3</a>)</li>
<li>The repaglinide component can cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Initiate PrandiMet at the lowest available dose in patients naive to meglitinide therapy. (<a href="#i4i_section_id_696c121f-08a8-4b60-bc3c-0afb5175ba3e">5.8</a>)</li>
<li>Metformin can cause vitamin B<span class="Sub">12</span> deficiency. Measure hematological parameters annually. (<a href="#i4i_section_id_427570d1-a2e3-4e3c-8251-66e9f2dd5eb5">5.9</a>) </li>
<li>May need to discontinue PrandiMet and temporarily use insulin if glycemic control deteriorates during periods of stress or if there is decreased intake of fluids and food (e.g., <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, surgery). (<a href="#i4i_section_id_bea75c2d-6374-432a-ae49-6174ffdaa05c">5.10</a>)</li>
<li>There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with PrandiMet or any other oral anti-diabetic drug. (<a href="#i4i_section_id_ccaa324d-4be7-46de-9ec4-95610ed29999">5.15</a>) </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> were the most common adverse reactions (≥10%) reported among patients treated with repaglinide in combination with metformin HCl, occurring more frequently than among patients treated with repaglinide alone or metformin HCl alone. (<a href="#i4i_section_id_f823c055-eded-46a8-a402-69f2d5ffeff4">6.2</a>)</li>
<li>Gastrointestinal reactions (e.g., <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>) are the most common adverse reactions with metformin HCl treatment and are more frequent at higher metformin HCl doses. (<a href="#i4i_section_id_c40d2ce1-727d-4017-ac4b-77527e9a1fa9">6.1</a>, <a href="#i4i_section_id_f823c055-eded-46a8-a402-69f2d5ffeff4">6.2</a>) <p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk at 1-800-727-6500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Cationic drugs eliminated by renal tubular secretion may interfere with metformin elimination: use with caution. (<a href="#i4i_section_id_bfba9d9e-891c-4074-a8c9-b372cfb63c19">7.1</a>)</li>
<li>Repaglinide is partly metabolized by CYP2C8 and CYP3A4. Use caution in patients taking inhibitors and/or inducers of CYP2C8 and CYP3A4. (<a href="#i4i_section_id_8dda359b-a02f-42e1-9da8-532ad7523efd">7.2</a>) </li>
</ul></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 4/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Radiologic Studies with Intravascular Iodinated Contrast Materials</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Impaired Hepatic Function</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Alcohol Intake</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Combination with NPH-insulin</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Drug Interactions</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Vitamin B<span class="Sub">12</span> Levels</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Surgical Procedures</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Loss of Control of Blood Glucose</a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Use of Concomitant Medications Affecting Renal Function or Metformin Disposition </a></h2>
<h2><a href="#section-5.13" class="toc">5.13 <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">Hypoxic</span> States</a></h2>
<h2><a href="#section-5.14" class="toc">5.14 Change in Clinical Status of Patients with Previously Controlled Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></a></h2>
<h2><a href="#section-5.15" class="toc">5.15 Macrovascular Outcomes</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Most Frequently Observed Adverse Reactions</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Clinical Trial Experience</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Cationic Drugs</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 CYP2C8 and CYP3A4 Inhibitors/Inducers</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Patients with Inadequate Glycemic Control on Metformin HCl Monotherapy</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Physician Instructions</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 Laboratory Tests</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_6e621880-39a8-4f65-8e13-63420d02f4bd"></a><a name="section-1"></a><p></p>
<h1>WARNING: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span></h1>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is a rare but serious complication that can occur due to metformin accumulation. The risk increases with conditions such as <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, excess alcohol intake, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and acute <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</span></p>
<p><span class="Bold">The onset of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> often is subtle, and accompanied only by nonspecific symptoms such as <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span></span><span class="Bold">, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, increasing <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and nonspecific <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal distress</span>.</span></p>
<p><span class="Bold">Laboratory abnormalities include low pH, increased <span class="product-label-link" type="condition" conceptid="4009397" conceptname="Anion gap">anion gap</span> and elevated blood lactate.</span></p>
<p><span class="Bold">If <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> is suspected, </span><span class="Bold">PrandiMet</span><span class="Bold"> should be discontinued and the patient hospitalized immediately [<span class="Italics">see <a href="#i4i_section_id_14e0b124-f6b0-4755-b467-9dff94d37911">Warnings and Precautions (5.1)</a></span>]. </span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_76496ea5-4e88-456c-9481-c65aacf7de27"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">PrandiMet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus who are already treated with a meglitinide and metformin HCl or who have inadequate glycemic control on a meglitinide alone or metformin HCl alone. </p>
<p><span class="Italics">Important Limitations of Use</span>:</p>
<p>PrandiMet should not be used in patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or for the treatment of <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>, as it would not be effective in these settings. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_8c486c4c-6492-4d80-9147-d1ed763548a0"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Italics">Recommended Dosing</span></p>
<p>The dosage of PrandiMet should be individualized on the basis of the patient's current regimen, effectiveness and tolerability. PrandiMet can be administered 2 to 3 times a day up to a maximum daily dose of 10 mg repaglinide/2500 mg metformin HCl. No more than 4 mg repaglinide/1000 mg metformin HCl should be taken per meal. Initiation and maintenance of combination therapy with PrandiMet should be individualized to the patient, and at the discretion of the health care provider. Blood glucose monitoring should be performed to determine the therapeutic response to PrandiMet.</p>
<p>PrandiMet doses should usually be taken within 15 minutes prior to the meal but the timing can vary from immediately preceding the meal up to 30 minutes before the meal. Patients who skip a meal should be instructed to skip the PrandiMet dose for that meal.</p>
<p><span class="Italics">Patients Inadequately Controlled with Metformin </span><span class="Italics">HCl</span><span class="Italics"></span><span class="Italics">Monotherapy</span></p>
<p>If therapy with a combination tablet containing repaglinide and metformin HCl is considered appropriate for a patient with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus inadequately controlled with metformin HCl alone, the recommended starting dose of PrandiMet is 1 mg repaglinide/500 mg metformin HCl administered twice daily with meals, with gradual dose escalation (based on glycemic response) to reduce the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> with repaglinide.</p>
<p><span class="Italics">Patients Inadequately Controlled with </span><span class="Italics">Meglitinide</span><span class="Italics"></span><span class="Italics">Monotherapy</span></p>
<p>If therapy with a combination tablet containing repaglinide and metformin HCl is considered appropriate for a patient with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus inadequately controlled with repaglinide alone, the recommended starting dose of the metformin HCl component of PrandiMet should be 500 mg metformin HCl twice a day, with gradual dose escalation (based on glycemic response) to reduce gastrointestinal side effects associated with metformin HCl.</p>
<p><span class="Italics">Patients Currently Using </span><span class="Italics">Repaglinide</span><span class="Italics"> and Metformin </span><span class="Italics">HCl</span><span class="Italics"> Concomitantly</span></p>
<p>For patients switching from repaglinide co-administered with metformin HCl, PrandiMet can be initiated at the dose of repaglinide and metformin HCl similar to (but not exceeding) the patient's current doses, then may be titrated to the maximum daily dose as necessary to achieve targeted glycemic control.</p>
<p>No studies have been performed examining the safety and efficacy of PrandiMet in patients previously treated with other oral antihyperglycemic agents and switched to PrandiMet. Any change in therapy should be undertaken with care and with appropriate monitoring as changes in glycemic control can occur.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_838b2f4e-fa40-41ca-b922-8650993db636"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<ul>
<li>1 mg repaglinide /500mg metformin HCl tablets are yellow, biconvex, debossed with Novo Nordisk (Apis) bull symbol on one side, and strength indicated on the other side</li>
<li>2 mg repaglinide /500mg metformin HCl tablets are pink, biconvex, debossed with Novo Nordisk (Apis) bull symbol on one side, and strength indicated on the other side</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_762b4592-ea74-4134-b6f9-c6a51d185e23"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">PrandiMet is contraindicated in:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> (e.g., serum creatinine levels ≥1.5 mg/dL [males], ≥1.4 mg/dL [females], or abnormal creatinine clearance) [<span class="Italics">see <a href="#i4i_section_id_2a30a5f3-e661-46b1-869b-e1f487223b03">Warnings and Precautions (5.2)</a></span>].</li>
<li>Acute or chronic <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, including <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>. <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">Diabetic ketoacidosis</span> should be treated with insulin [<span class="Italics">see <a href="#i4i_section_id_14e0b124-f6b0-4755-b467-9dff94d37911">Warnings and Precautions (5.1)</a></span>].</li>
<li>Patients receiving gemfibrozil [<span class="Italics">see <a href="#i4i_section_id_fee49ddf-0ace-4b4e-95cf-eccaa63d3c4b">Warnings and Precautions (5.7)</a></span>, <span class="Italics"><a href="#i4i_section_id_8dda359b-a02f-42e1-9da8-532ad7523efd">Drug Interactions (7.2)</a></span>, <span class="Italics"><a href="#i4i_pharmacokinetics_id_abd94ac1-a1c5-446a-9b45-8399b7204620">Clinical Pharmacology (12.3)</a></span>].</li>
<li>Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to repaglinide, metformin HCl or any inactive ingredients in PrandiMet. </li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_e0f6d868-927d-4215-8a20-4feacfcaa694"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_14e0b124-f6b0-4755-b467-9dff94d37911"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span></h2>
<p class="First"><span class="Italics">Metformin hydrochloride</span></p>
<p><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is a rare, but serious, metabolic complication that can occur due to metformin accumulation during treatment with PrandiMet; when it occurs, it is fatal in approximately 50% of cases. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> may also occur in association with a number of pathophysiologic conditions, including <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, and whenever there is significant tissue <span class="product-label-link" type="condition" conceptid="4131044" conceptname="Hypoperfusion">hypoperfusion</span> and <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span>. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is characterized by elevated blood lactate levels (&gt;5 mmol/L), decreased blood pH, <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span> with an increased <span class="product-label-link" type="condition" conceptid="4009397" conceptname="Anion gap">anion gap</span>, and an increased lactate/<span class="product-label-link" type="condition" conceptid="4029769" conceptname="Pyruvic acid">pyruvate</span> ratio. When metformin is implicated as the cause of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, metformin plasma levels &gt;5 µg/mL are generally found.</p>
<p>The reported incidence of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> in patients receiving metformin HCl is very low (approximately 0.03 cases/1,000 patient-years of exposure, with approximately 0.015 fatal cases/1,000 patient-years of exposure). In more than 20,000 patient-years exposure to metformin HCl in clinical trials, there were no reports of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. Reported cases have occurred primarily in diabetic patients with significant <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, including both intrinsic <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> and renal <span class="product-label-link" type="condition" conceptid="4131044" conceptname="Hypoperfusion">hypoperfusion</span>, often in the setting of multiple concomitant medical/surgical problems and multiple concomitant medications. Patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> requiring pharmacologic management, in particular those with unstable or acute <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> who are at risk of <span class="product-label-link" type="condition" conceptid="4131044" conceptname="Hypoperfusion">hypoperfusion</span> and <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span>, are at increased risk of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. The risk of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> increases with the degree of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and the patient's age. The risk of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> may, therefore, be significantly decreased by regular monitoring of renal function in patients taking PrandiMet and by use of the minimum effective dose of PrandiMet. In particular, treatment of the elderly should be accompanied by careful monitoring of renal function. Treatment with PrandiMet should not be initiated in patients ≥80 years of age unless measurement of creatinine clearance demonstrates that renal function is not reduced, as these patients are more susceptible to developing <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. In addition, PrandiMet should be promptly withheld in the presence of any condition associated with <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, or <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>. Because impaired hepatic function may significantly limit the ability to clear lactate, PrandiMet should generally be avoided in patients with clinical or laboratory evidence of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>. Patients should be cautioned against excessive alcohol intake, either acute or chronic, when taking PrandiMet, since alcohol potentiates the effects of metformin HCl on lactate metabolism. In addition, PrandiMet should be temporarily discontinued prior to any intravascular radiocontrast study and for any surgical procedure [<span class="Italics">see <a href="#i4i_section_id_9dc1dd78-4eda-4c48-a45c-57e89d1b6f45">Warnings and Precautions (5.3)</a>, (<a href="#i4i_section_id_2d11e1db-a3f9-43c1-8e3b-773335a6c486">5.5</a>), and (<a href="#i4i_section_id_bea75c2d-6374-432a-ae49-6174ffdaa05c">5.10</a>)</span>]. </p>
<p>The onset of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> often is subtle, and accompanied only by nonspecific symptoms such as <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, increasing <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and nonspecific <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal distress</span>. There may be associated <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and resistant <span class="product-label-link" type="condition" conceptid="4228448" conceptname="Bradyarrhythmia">bradyarrhythmias</span> with more marked <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>. The patient and the patient's physician must be aware of the possible importance of such symptoms and the patient should be instructed to notify the physician immediately if they occur (see also Warnings and Precautions). PrandiMet should be withdrawn until the situation is clarified. Serum electrolytes, <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketones</span>, blood glucose and, if indicated, blood pH, lactate levels, and even blood metformin levels may be useful. Once a patient is stabilized on any dose level of PrandiMet, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>, which are common during initiation of therapy, are unlikely to be drug related. Later occurrence of <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> could be due to <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or other serious disease.</p>
<p>Levels of fasting venous plasma lactate above the upper limit of normal but less than 5 mmol/L in patients taking PrandiMet do not necessarily indicate impending <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> and may be explainable by other mechanisms, such as poorly controlled <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, vigorous physical activity or technical problems in sample handling [<span class="Italics">see <a href="#i4i_section_id_00d129ed-08b7-406e-98e2-eabf315c12c5">Warnings and Precautions (5.11)</a>, (<a href="#i4i_section_id_a9a28381-8d41-4f1d-957c-c44ee29c8839">5.14</a>)</span>].</p>
<p><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> should be suspected in any diabetic patient with <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> lacking evidence of <span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">ketoacidosis</span> (<span class="product-label-link" type="condition" conceptid="4171926" conceptname="Ketonuria">ketonuria</span> and <span class="product-label-link" type="condition" conceptid="4060404" conceptname="Acetonemia">ketonemia</span>).</p>
<p><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is a medical emergency that must be treated in a hospital setting. In a patient with <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> who is taking PrandiMet, the drug should be discontinued immediately and general supportive measures promptly instituted. Because metformin HCl is dialyzable (with a clearance of up to 170 mL/min under good hemodynamic conditions), prompt hemodialysis is recommended to correct the <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> and remove the accumulated metformin. Such management often results in prompt reversal of symptoms and recovery [<span class="Italics">see <a href="#i4i_contraindications_id_762b4592-ea74-4134-b6f9-c6a51d185e23">Contraindications (4)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2a30a5f3-e661-46b1-869b-e1f487223b03"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> should not receive PrandiMet <span class="Italics">[see <a href="#i4i_section_id_14e0b124-f6b0-4755-b467-9dff94d37911">Warnings and Precautions (5.1)</a>, <a href="#i4i_contraindications_id_762b4592-ea74-4134-b6f9-c6a51d185e23">Contraindications (4)</a></span>].</p>
<p>As metformin is substantially excreted by the kidney, before initiation of therapy with PrandiMet and at least annually thereafter, renal function should be assessed and verified as normal. In patients in whom development of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is anticipated, renal function should be assessed more frequently and PrandiMet discontinued if evidence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is present [<span class="Italics">see <a href="#i4i_pharmacokinetics_id_abd94ac1-a1c5-446a-9b45-8399b7204620">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9dc1dd78-4eda-4c48-a45c-57e89d1b6f45"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Radiologic Studies with Intravascular Iodinated Contrast Materials</h2>
<p class="First">Intravascular contrast studies with iodinated materials can lead to acute alteration of renal function and have been associated with <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> in patients receiving metformin HCl [<span class="Italics">see <a href="#i4i_contraindications_id_762b4592-ea74-4134-b6f9-c6a51d185e23">Contraindications (4)</a></span>]. Therefore, in patients in whom any such study is planned, PrandiMet should be temporarily discontinued at the time of or prior to the procedure, and withheld for 48 hours subsequent to the procedure and reinstituted only after renal function has been re-evaluated and found to be normal. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1400adc2-3342-429c-b074-b25eb7e02708"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Impaired Hepatic Function</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span> has been associated with some cases of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. Therefore, PrandiMet should generally be avoided in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [<span class="Italics">see <a href="#i4i_pharmacokinetics_id_abd94ac1-a1c5-446a-9b45-8399b7204620">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2d11e1db-a3f9-43c1-8e3b-773335a6c486"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Alcohol Intake</h2>
<p class="First">Alcohol potentiates the effect of metformin on lactate metabolism. Patients should be warned against excessive alcohol intake while receiving PrandiMet. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_baba9f2e-cbee-46b5-b168-e8b511332962"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Combination with NPH-insulin</h2>
<p class="First"><span class="Italics">Repaglinide</span></p>
<p>Repaglinide is not indicated for use in combination with NPH-insulin.</p>
<p>Across seven controlled clinical trials, there were six serious adverse events (1.4%) of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> with repaglinide in combination with NPH-insulin compared to one event (0.3%) in patients using insulin alone [<span class="Italics">see <a href="#i4i_section_id_f823c055-eded-46a8-a402-69f2d5ffeff4">Adverse Reactions (6.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fee49ddf-0ace-4b4e-95cf-eccaa63d3c4b"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Drug Interactions</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Repaglinide</span><span class="XmChange"> is partly metabolized by CYP2C8 and CYP3A4 and appears to be a substrate for active hepatic uptake transporter (organic anion transporting protein OATP1B1).  Drugs that inhibit CYP2C8, CYP3A4, or OATP1B1 (e.g., cyclosporine) may increase plasma concentrations of </span><span class="XmChange">repaglinide</span><span class="XmChange">. Dose reduction of </span><span class="XmChange">repaglinide</span><span class="XmChange"> may be needed <span class="Italics">[see </span></span><span class="Italics" style="border-left:1px solid;"><a href="#i4i_section_id_8dda359b-a02f-42e1-9da8-532ad7523efd">Drug Interactions (7.2)</a><span class="XmChange"> and </span><a href="#i4i_pharmacokinetics_id_abd94ac1-a1c5-446a-9b45-8399b7204620">Clinical Pharmacology (12.3)</a><span class="XmChange">].</span></span></p>
<p>Gemfibrozil significantly increased repaglinide exposure. Therefore, patients should not take PrandiMet with gemfibrozil [<span class="Italics">see <a href="#i4i_contraindications_id_762b4592-ea74-4134-b6f9-c6a51d185e23">Contraindications (4)</a> and <a href="#i4i_pharmacokinetics_id_abd94ac1-a1c5-446a-9b45-8399b7204620">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_696c121f-08a8-4b60-bc3c-0afb5175ba3e"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h2>
<p class="First">Most blood glucose-lowering drugs, including repaglinide, can cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Patients who have not previously been treated with a meglitinide should be started on the lowest available repaglinide component of PrandiMet to reduce the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Elderly, debilitated or malnourished patients and those with adrenal or <span class="product-label-link" type="condition" conceptid="4254542" conceptname="Hypopituitarism">pituitary insufficiency</span> or alcohol <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> are particularly susceptible to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> may be difficult to recognize in the elderly and in people who are taking β-adrenergic blocking drugs [<span class="Italics">see <a href="#i4i_section_id_c40d2ce1-727d-4017-ac4b-77527e9a1fa9">Adverse Reactions (6.1)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_427570d1-a2e3-4e3c-8251-66e9f2dd5eb5"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Vitamin B<span class="Sub">12</span> Levels</h2>
<p class="First">In controlled clinical trials of metformin HCl of 29 weeks' duration, a decrease to subnormal levels of previously normal serum vitamin B<span class="Sub">12</span> levels, without clinical manifestations, was observed in approximately 7% of patients. This finding, possibly due to interference with B<span class="Sub">12</span> absorption from the B<span class="Sub">12</span>-intrinsic factor complex, is rarely associated with <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and appears to be rapidly reversible with discontinuation of metformin HCl or vitamin B<span class="Sub">12</span> supplementation. Measurement of hematologic parameters on an annual basis is advised in patients on PrandiMet and any apparent abnormalities should be appropriately investigated and managed.</p>
<p>Certain individuals (those with inadequate vitamin B<span class="Sub">12</span> or calcium intake or absorption) appear to be predisposed to developing subnormal vitamin B<span class="Sub">12</span> levels. In these patients, routine serum vitamin B<span class="Sub">12</span> measurements at 2- to 3-year intervals may be useful. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bea75c2d-6374-432a-ae49-6174ffdaa05c"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Surgical Procedures</h2>
<p class="First">Use of PrandiMet should be temporarily suspended for any surgical procedure (except minor procedures not associated with restricted intake of food and fluids) and should not be restarted until the patient's oral intake has resumed and renal function has been evaluated as normal.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_00d129ed-08b7-406e-98e2-eabf315c12c5"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Loss of Control of Blood Glucose</h2>
<p class="First">When a patient stabilized on any diabetic regimen is exposed to stress such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, or surgery, a temporary loss of glycemic control may occur. At such times, it may be necessary to withhold PrandiMet and temporarily administer insulin. PrandiMet may be reinstituted after the acute episode is resolved.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c01dd748-c21e-42d6-ae0e-4eb5ce23eed7"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Use of Concomitant Medications Affecting Renal Function or Metformin Disposition </h2>
<p class="First">Concomitant medication(s) that may affect renal function or result in significant hemodynamic change or may interfere with the disposition of metformin, such as cationic drugs that are eliminated by renal tubular secretion [<span class="Italics">see <a href="#i4i_section_id_bfba9d9e-891c-4074-a8c9-b372cfb63c19">Drug Interactions (7.1)</a></span>] should be used with caution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_396aafb7-2baa-4578-bd30-b79cf3771691"></a><a name="section-5.13"></a><p></p>
<h2>5.13 <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">Hypoxic</span> States</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">Cardiovascular collapse</span> (<span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>) from whatever cause, acute <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, and other conditions characterized by <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span> have been associated with <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> and may also cause prerenal <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>. When such events occur in patients receiving PrandiMet, the drug should be promptly discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a9a28381-8d41-4f1d-957c-c44ee29c8839"></a><a name="section-5.14"></a><p></p>
<h2>5.14 Change in Clinical Status of Patients with Previously Controlled Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></h2>
<p class="First">A patient with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> previously well-controlled on PrandiMet who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of <span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">ketoacidosis</span> or <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. Evaluation should include serum electrolytes and <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketones</span>, blood glucose and, if indicated, blood pH, lactate, <span class="product-label-link" type="condition" conceptid="4029769" conceptname="Pyruvic acid">pyruvate</span>, and metformin levels. If <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> of either form occurs, PrandiMet must be stopped immediately and other appropriate corrective measures initiated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ccaa324d-4be7-46de-9ec4-95610ed29999"></a><a name="section-5.15"></a><p></p>
<h2>5.15 Macrovascular Outcomes</h2>
<p class="First">There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with PrandiMet or any other oral anti-diabetic drug. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_e91020e5-8784-4a5f-9483-5b76bd2b338e"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c40d2ce1-727d-4017-ac4b-77527e9a1fa9"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Most Frequently Observed Adverse Reactions</h2>
<p class="First"><span class="Italics">Repaglinide</span></p>
<p>In clinical trials of repaglinide, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> is the most common adverse reaction (&gt; 5%) leading to withdrawal of patients treated with repaglinide.</p>
<p><span class="Italics">Metformin </span><span class="Italics">HCl</span></p>
<p>Gastrointestinal reactions (e.g., <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>) are the most common adverse reactions (&gt; 5%) with metformin HCl treatment and are more frequent at higher metformin HCl doses.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f823c055-eded-46a8-a402-69f2d5ffeff4"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Clinical Trial Experience</h2>
<p class="First">Because clinical trials are conducted under varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p><span class="Italics">Patients with Inadequate Glycemic Control on Metformin </span><span class="Italics">HCl</span><span class="Italics"></span><span class="Italics">Monotherapy</span></p>
<p>Table 1 summarizes the most common adverse reactions occurring in a 6-month randomized study of repaglinide added to metformin HCl in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> inadequately controlled on metformin HCl alone.</p>
<a name="_Refid_49ee3702-9592-422f-abc6-57f058eaa"></a><table>
<caption><span>Table 1: Repaglinide added to metformin HCl in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> inadequately controlled on metformin HCl alone. Adverse reaction reported (regardless of Investigator Assessment of Causality) in ≥10% of patients receiving combination therapy<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col width="38%">
<col width="23%">
<col width="22%">
<col width="17%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Intent to treat population</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>There were no cases of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> requiring the assistance of another person)</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule"></td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First">Coadministered repaglinide</p>
<p>and metformin HCl</p>
</td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First">Metformin HCl</p>
<p>monotherapy</p>
</td>
<td class="Botrule Toprule" align="center">
<p class="First">Repaglinide</p>
<p>monotherapy</p>
</td>
</tr>
<tr>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule" align="center"><p class="First">N (%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">N (%)</p></td>
<td class="Botrule" align="center"><p class="First">N (%)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">No. of Patients Exposed</p></td>
<td class="Botrule Rrule" align="center"><p class="First">27</p></td>
<td class="Botrule Rrule" align="center"><p class="First">27</p></td>
<td class="Botrule" align="center"><p class="First">28</p></td>
</tr>
<tr>
<td class="Rrule"><p class="First">Gastrointestinal System Disorder</p></td>
<td class="Rrule" align="center"><p class="First">9 (33)</p></td>
<td class="Rrule" align="center"><p class="First">13 (48)</p></td>
<td align="center"><p class="First">10 (36)</p></td>
</tr>
<tr>
<td class="Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Rrule" align="center"><p class="First">5 (19)</p></td>
<td class="Rrule" align="center"><p class="First">8 (30)</p></td>
<td align="center"><p class="First">2 (7)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">4 (15)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2 (7)</p></td>
<td class="Botrule" align="center"><p class="First">1 (4)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Symptomatic <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">9 (33)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0 (0)</p></td>
<td class="Botrule" align="center"><p class="First">3 (11)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">6 (22)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4 (15)</p></td>
<td class="Botrule" align="center"><p class="First">3 (11)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">3 (11)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3 (11)</p></td>
<td class="Botrule" align="center"><p class="First">3 (11)</p></td>
</tr>
</tbody>
</table>
<p><span class="Italics">Cardiovascular Events in </span><span class="Italics">repaglinide</span><span class="Italics"></span><span class="Italics">monotherapy</span><span class="Italics"> trials</span></p>
<p>In one-year trials comparing repaglinide to sulfonylurea drugs, the incidence of angina was 1.8% for both treatments, with an incidence of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> of 1.8% for repaglinide and 1.0% for sulfonylureas. The incidence of other selected cardiovascular events (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, abnormal electrocardiogram, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>) was ≤ 1% and not different between repaglinide and the comparator drugs.</p>
<p>The incidence of total serious cardiovascular adverse events, including <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, was higher for repaglinide (51/1228 or 4%) than for sulfonylurea drugs (13/498 or 3%) in controlled clinical trials. In 1-year controlled trials, repaglinide treatment was not associated with excess mortality when compared to the rates observed with other oral hypoglycemic agent therapies such as glyburide and glipizide.</p>
<p>Seven controlled clinical trials included repaglinide combination therapy with NPH-insulin (n=431), insulin formulations alone (n=388) or other combinations (sulfonylurea plus NPH-insulin or repaglinide plus metformin HCl) (n=120). There were six serious adverse events of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> in patients treated with repaglinide plus NPH-insulin (1.4%) from two studies, and one event in patients using insulin formulations alone from another study (0.3%) <span class="Italics">[</span><span class="Italics">see</span><span class="Italics"></span><span class="Italics"><a href="#i4i_section_id_baba9f2e-cbee-46b5-b168-e8b511332962">Warnings and Precautions (5.6)</a></span><span class="Italics">].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7231be91-7fb7-4ecf-aff3-bd739cd471ff"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Postmarketing Experience</h2>
<p class="First"><span class="Italics">Repaglinide</span></p>
<p>The following additional adverse reactions have been identified during postapproval use of repaglinide. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or a causal relationship to drug exposure.</p>
<p>Postmarketing experience with repaglinide includes infrequent reports of the following adverse events; <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>, and severe hepatic dysfunction including <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_06d0b8c3-a4b2-426a-889c-5fa5018d1ceb"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bfba9d9e-891c-4074-a8c9-b372cfb63c19"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Cationic Drugs</h2>
<p class="First">Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. Careful patient monitoring and dose adjustment of PrandiMet and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system [<span class="Italics">see <a href="#i4i_pharmacokinetics_id_abd94ac1-a1c5-446a-9b45-8399b7204620">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8dda359b-a02f-42e1-9da8-532ad7523efd"></a><a name="section-7.2"></a><p></p>
<h2>7.2 CYP2C8 and CYP3A4 Inhibitors/Inducers</h2>
<p class="First">Repaglinide is metabolized by CYP2C8 and to a lesser extent by CYP3A4. Drugs that inhibit 2C8 (gemfibrozil, trimethoprim, deferasirox), inhibit 3A4 (itraconazole, ketaconazole), or induce CYP2C8/3A4 (rifampin) may alter the pharmacokinetics and pharmacodynamics of repaglinide. <span class="Italics">In vivo</span> data from a study that evaluated the co-administration of gemfibrozil and repaglinide in healthy subjects showed a significant increase in repaglinide blood levels. Administration of PrandiMet and gemfibrozil to the same patient is not recommended [<span class="Italics">see <a href="#i4i_section_id_fee49ddf-0ace-4b4e-95cf-eccaa63d3c4b">Warnings and Precautions (5.7)</a> and <a href="#i4i_pharmacokinetics_id_abd94ac1-a1c5-446a-9b45-8399b7204620">Clinical Pharmacology (12.3)</a></span>].</p>
<p>Repaglinide exposures are increased more than 20-fold in patients taking both gemfibrozil and itraconazole [<span class="Italics">see <a href="#i4i_contraindications_id_762b4592-ea74-4134-b6f9-c6a51d185e23">Contraindications (4)</a> and <a href="#i4i_pharmacokinetics_id_abd94ac1-a1c5-446a-9b45-8399b7204620">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_731c3356-bedd-4120-bfcb-b009a204edbe"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_f680a81e-9dfc-4ef4-b84d-dc8b33bb34eb"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category C. </p>
<p>There are no adequate and well-controlled studies in pregnant women with PrandiMet or its individual components. Because animal reproduction studies are not always predictive of human response, PrandiMet like other antidiabetic medications, should be used during pregnancy only if clearly needed.</p>
<p>No animal studies have been conducted with the combined products in PrandiMet. The following data are based on findings in studies performed with repaglinide or metformin individually.    </p>
<p><span class="Italics">Repaglinide</span></p>
<p>Repaglinide was not teratogenic in rats at doses 40 times, and rabbits approximately 0.8 times the clinical exposure (on a mg/m<span class="Sup">2</span> basis) throughout pregnancy. Offspring of rat dams exposed to repaglinide at 15 times clinical exposure on a mg/m<span class="Sup">2</span> basis during days 17 to 22 of gestation and during lactation developed nonteratogenic skeletal deformities consisting of shortening, thickening, and bending of the humerus during the postnatal period. This effect was not seen at doses up to 2.5 times clinical exposure (on a mg/m<span class="Sup">2</span> basis) on days 1 to 22 of pregnancy or at higher doses given during days 1 to 16 of pregnancy. Relevant human exposure has not occurred to date and therefore the safety of repaglinide administration throughout pregnancy or lactation cannot be established.</p>
<p><span class="Italics">Metformin </span><span class="Italics">HCl</span></p>
<p>Metformin HCl alone was not teratogenic in rats or rabbits at doses up to 600 mg/kg/day. This represents an exposure of approximately two and six times the near-maximal efficacious human daily dose of 2000 mg of the metformin HCl component of PrandiMet based on body surface area comparisons for rats and rabbits, respectively. Determination of fetal concentrations demonstrated a partial placental barrier to metformin. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_f76dcf7b-b99d-47b3-a4a0-6e589531bf18"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">No studies in lactating animals have been conducted with the PrandiMet fixed dose combination. In studies performed with individual components, both repaglinide and metformin are excreted into milk of lactating rats.</p>
<p><span class="Italics">Repaglinide</span></p>
<p>In rat reproduction studies, measurable levels of repaglinide were detected in the breast milk of the dams and lowered blood glucose levels were observed in the pups. Cross fostering studies indicated that skeletal changes could be induced in control pups nursed by treated dams, although this occurred to a lesser degree than those pups treated in utero.</p>
<p><span class="Italics">Metformin </span><span class="Italics">HCl</span></p>
<p>Studies in lactating rats with metformin HCl show that it is excreted into milk and reaches levels comparable to those in plasma.</p>
<p>It is not known whether repaglinide or metformin are excreted in human milk. PrandiMet is not recommended in nursing mothers because it may potentially cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in nursing infants. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_c9d02986-bce4-47c0-89e3-b601e32f93a7"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of PrandiMet in pediatric patients have not been established. PrandiMet is not recommended for use in children.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_29d852d2-58ac-47f5-815f-7ad7472a499d"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Healthy volunteers treated with repaglinide 2 mg before each of 3 meals, showed no significant differences in repaglinide pharmacokinetics between the group of patients &lt;65 years of age and those ≥65 years of age.</p>
<p>In patients with advanced age, PrandiMet should be carefully titrated to establish the minimum dose for adequate glycemic effect, because aging is associated with reduced renal function. In elderly patients, particularly those ≥80 years of age, dose adjustment of PrandiMet should be based on a careful assessment of renal function [<span class="Italics">see <a href="#i4i_section_id_14e0b124-f6b0-4755-b467-9dff94d37911">Warnings and Precautions (5.1</a> and <a href="#i4i_section_id_2a30a5f3-e661-46b1-869b-e1f487223b03">5.2</a>), <a href="#i4i_contraindications_id_762b4592-ea74-4134-b6f9-c6a51d185e23">Contraindications (4)</a>, <a href="#i4i_pharmacokinetics_id_abd94ac1-a1c5-446a-9b45-8399b7204620">Clinical Pharmacology (12.3)</a></span>]. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_aa593e56-45bd-4f93-944d-2b25e2c9993a"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First"><span class="Italics">PrandiMet</span></p>
<p>No data are available with regard to <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of PrandiMet. Findings related to the individual active substances are listed below.</p>
<p><span class="Italics">Repaglinide</span></p>
<p>In a clinical trial, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> were reported in subjects receiving increasing doses of repaglinide up to 80 mg a day for 14 days. <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> did not occur when meals were given with these high doses. </p>
<p>Hypoglycemic symptoms without <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> or neurologic findings should be treated aggressively with oral glucose and adjustments in drug dosage and/or meal patterns. Close monitoring should continue until the physician is assured that the patient is out of danger. Patients should be closely monitored for a minimum of 24 to 48 hours, since <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may recur after apparent clinical recovery. There is no evidence that repaglinide is dialyzable using hemodialysis. Severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemic reactions</span> with <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, or other neurological impairment occur infrequently, but constitute medical emergencies requiring immediate hospitalization. If <span class="product-label-link" type="condition" conceptid="380688" conceptname="Hypoglycemic coma">hypoglycemic coma</span> is diagnosed or suspected, the patient should be given a rapid intravenous injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of more dilute (10%) glucose solution at a rate that will maintain the blood glucose at a level above 100 mg/dL.</p>
<p><span class="Italics">Metformin </span><span class="Italics">HCl</span></p>
<p><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> of metformin HCl has occurred, including ingestion of amounts greater than 50 grams. <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> was reported in approximately 10% of cases, but no causal association with metformin HCl has been established. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> has been reported in approximately 32% of metformin HCl <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> cases <span class="Italics">[see <a href="#i4i_section_id_14e0b124-f6b0-4755-b467-9dff94d37911">Warnings and Precautions (5.1)</a></span>]. Metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, hemodialysis may be useful for removal of accumulated drug from patients in whom metformin HCl overdosage is suspected. </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_d91ae797-56af-411a-a0ef-e63a8cce2b9b"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">PrandiMet (repaglinide and metformin HCl) tablets contain two oral antihyperglycemic drugs used in the management of type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>: repaglinide and metformin HCl. The concomitant use of repaglinide and metformin HCl has been previously approved based on clinical trials in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> inadequately controlled on exercise, diet, and metformin HCl alone. </p>
<p>Repaglinide, S(+)2-ethoxy-4(2((3-methyl-1-(2-(1-piperidinyl) phenyl)-butyl) amino)-2-oxoethyl) benzoic acid, is chemically unrelated to the oral sulfonylurea insulin secretagogues. Repaglinide is a white to off-white powder with molecular formula C<span class="Sub">27</span> H<span class="Sub">36</span> N<span class="Sub">2</span> O<span class="Sub">4</span> and a molecular weight of 452.6 with the structural formula as shown below. Repaglinide is freely soluble in methanol and ethanol. The pKa of repaglinide in acid is 3.9, and the pKa in amine is 6.0. </p>
<p><span class="Bold">Structural formula of </span><span class="Bold">Repaglinide</span></p>
<div class="Figure">
<a name="id986"></a><img alt="Fig. 1 - Structural Formula of Repaglinide" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5be33711-b77d-4a01-87c8-3b2618c16e8f&amp;name=ad18920e-7672-4fba-841a-6607835064d2-01.jpg">
</div>
<p>Metformin HCl (N,N-dimethylimidodicarbonimidic diamide hydrochloride) is not chemically or pharmacologically related to any other classes of oral antihyperglycemic agents. Metformin HCl is a white to off-white crystalline compound with a molecular formula of C<span class="Sub">4</span>H<span class="Sub">11</span>N<span class="Sub">5</span>∙HCl and a molecular weight of 165.63. Metformin HCl is freely soluble in water and is practically insoluble in acetone, ether, and chloroform. The pKa of metformin HCl is 12.4. The pH of a 1% aqueous solution of metformin HCl is 6.68. The structural formula of metformin HCl is: </p>
<p><span class="Bold">Structural formula of Metformin </span><span class="Bold">HCl</span></p>
<div class="Figure">
<a name="id993"></a><img alt="Fig. 2 - Structural Formula of Metformin HCl" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5be33711-b77d-4a01-87c8-3b2618c16e8f&amp;name=ad18920e-7672-4fba-841a-6607835064d2-02.jpg">
</div>
<p>PrandiMet is available as a tablet for oral administration containing 1 mg repaglinide with 500 mg metformin HCl (1 mg/500 mg) or 2 mg repaglinide with 500 mg metformin HCl (2 mg/500 mg) formulated with the following inactive ingredients: poloxamer 188, microcrystalline cellulose, polacrillin potassium, magnesium stearate, hypromellose 3cp or 6cp, povidone, meglumine, sorbitol, talc, titanium dioxide, red or yellow iron oxide, and polyethylene glycol. Propylene glycol is present in the 2 mg/500 mg PrandiMet tablets.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_06fc55fe-9add-40bd-a346-e6a9c706cb61"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_b2abe285-d9dd-4626-ae8d-0576de34a301"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First"><span class="Italics">PrandiMet</span></p>
<p>PrandiMet combines two anti-hyperglycemic agents with different mechanisms of action to improve glycemic control in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</p>
<p>Repaglinide lowers blood glucose levels by stimulating the release of insulin from the pancreas. This action is dependent upon functioning beta (ß) cells in the pancreatic islets.</p>
<p>Repaglinide closes ATP-dependent potassium channels in the ß-cell membrane by binding at characterizable sites. This potassium channel blockade depolarizes the ß-cell, which leads to an opening of calcium channels. The resulting increased calcium influx induces insulin secretion. The ion channel mechanism is highly tissue selective with low affinity for heart and skeletal muscle.</p>
<p>Metformin is an anti-hyperglycemic agent, which improves glucose tolerance in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> by lowering both the basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may actually decrease. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_abd94ac1-a1c5-446a-9b45-8399b7204620"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Italics">PrandiMet</span></p>
<p>The results of a bioequivalence study in healthy subjects (Table 2) demonstrated that PrandiMet (repaglinide/metformin HCl) 1 mg/500 mg and 2 mg/500 mg combination tablets are bioequivalent to co-administration of corresponding doses of repaglinide and metformin HCl as individual tablets.</p>
<p>Repaglinide dose proportionality was demonstrated for PrandiMet (2 mg/500 mg) and PrandiMet (1 mg/500 mg). </p>
<a name="_Refid_07aa629c-4e3d-4b55-8751-87fe154d0"></a><table>
<caption><span>Table 2. Mean (SD) Pharmacokinetic Parameters for Repaglinide and Metformin</span></caption>
<col width="25%">
<col width="13%">
<col width="33%">
<col width="30%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule"></td>
<td class="Botrule Rrule Toprule"></td>
<td class="Botrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Pharmacokinetic Parameter</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">Treatment</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">AUC (</span><span class="Bold">ng∙h</span><span class="Bold">/mL</span>)</p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">C<span class="Sub">max</span></span><span class="Bold"> (</span><span class="Bold">ng</span><span class="Bold">/mL)</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Repaglinide</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">A</p></td>
<td class="Botrule Rrule" align="center"><p class="First">55</p></td>
<td class="Botrule Rrule" align="center"><p class="First">34.5 (13.3)</p></td>
<td class="Botrule" align="center"><p class="First">26.0 (13.7)</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">B</p></td>
<td class="Botrule Rrule" align="center"><p class="First">55</p></td>
<td class="Botrule Rrule" align="center"><p class="First">35.0 (13.2)</p></td>
<td class="Botrule" align="center"><p class="First">23.7 (12.5)</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">C</p></td>
<td class="Botrule Rrule" align="center"><p class="First">55</p></td>
<td class="Botrule Rrule" align="center"><p class="First">17.6 (6.6)</p></td>
<td class="Botrule" align="center"><p class="First">12.9 (6.9)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Metformin</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">A</p></td>
<td class="Botrule Rrule" align="center"><p class="First">55</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6041.9 (1494.6)</p></td>
<td class="Botrule" align="center"><p class="First">838.8 (210.2)</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">B</p></td>
<td class="Botrule Rrule" align="center"><p class="First">55</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5871.6 (1352.6)</p></td>
<td class="Botrule" align="center"><p class="First">805.9 (160.3)</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">C</p></td>
<td class="Botrule Rrule" align="center"><p class="First">55</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5948.9 (1442.0)</p></td>
<td class="Botrule" align="center"><p class="First">799.4 (174.6)</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule" colspan="4">
<p class="First">Treatment:</p>
<p>A = 2 mg/500 mg PrandiMet tablet</p>
<p>B = 2 mg repaglinide tablet + 500 mg metformin HCl tablet</p>
<p>C = 1 mg/500 mg PrandiMet tablet</p>
</td></tr>
</tbody>
</table>
<p><span class="Underline">Absorption and Bioavailability</span></p>
<p><span class="Italics">Repaglinide</span>: After single and multiple oral doses in healthy subjects or in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, peak plasma drug levels (C<span class="Sub">max</span>) occur within 1 hour (T<span class="Sub">max</span>). Repaglinide is eliminated from the blood stream with a half-life of approximately 1 hour. The mean absolute bioavailability is 56%. When repaglinide was given with food, the mean T<span class="Sub">max</span> was not changed, but the mean C<span class="Sub">max</span> and AUC (area under the time/plasma concentration curve) were decreased 20% and 12.4%, respectively.</p>
<p><span class="Italics">Metformin </span><span class="Italics">HCl</span>: The absolute bioavailability of a 500 mg metformin HCl tablet given under fasting conditions is approximately 50% to 60%. Studies using single oral doses of metformin HCl tablets of 500 mg to 1,500 mg, and 850 mg to 2,550 mg, indicate that there is a lack of dose proportionality with increasing doses, which is due to decreased absorption rather than an alteration in elimination. Food decreases the extent of and slightly delays the absorption of metformin, as shown by approximately a 40% lower peak concentration (C<span class="Sub">max</span>), a 25% lower area under plasma concentration (AUC) and a 35-minute prolongation of time to peak plasma concentration (T<span class="Sub">max</span>) following administration of a single 850 mg tablet of metformin HCl with food, compared to the same tablet strength administered fasting. The clinical relevance of these decreases is unknown. </p>
<p><span class="Underline">Distribution</span></p>
<p><span class="Italics">Repaglinide</span>: After intravenous (IV) dosing in healthy subjects, the volume of distribution at steady state (Vss) was 31 L, and the total body clearance (CL) was 38 L/h. Protein binding and binding to human serum albumin was greater than 98%.</p>
<p><span class="Italics">Metformin </span><span class="Italics">HCl</span>: The apparent volume of distribution (V/F) of metformin following single oral dose of 850 mg averaged 654 ± 358 L. Metformin is negligibly bound to plasma proteins. Metformin partitions into erythrocytes, most likely as a function of time. At usual clinical doses and dosing schedules of metformin HCl, steady state plasma concentrations of metformin are reached within 24-48 hours and are generally &lt; 1 μg/mL. During controlled clinical trials, maximum metformin plasma levels did not exceed 5 μg/mL, even at maximum doses. </p>
<p><span class="Underline">Metabolism and Elimination</span></p>
<p><span class="Italics">Repaglinide</span>: Repaglinide is completely metabolized by oxidative biotransformation and direct conjugation with glucuronic acid after either an intravenous or oral dose. The major metabolites are an oxidized dicarboxylic acid (M2), the aromatic amine (M1), and the acyl glucuronide (M7). The cytochrome P-450 enzyme system, specifically 2C8 and 3A4, have been shown to be involved in the N-dealkylation of repaglinide to M2 and the further oxidation to M1. Metabolites do not contribute to the glucose-lowering effect of repaglinide. Within 96 hours after dosing with <span class="Sup">14</span>C-repaglinide as a single, oral dose, approximately 90% of the radiolabel was recovered in the feces and approximately 8% in the urine. Only 0.1% of the dose is cleared in the urine as parent compound. The major metabolite (M2) accounted for 60% of the administered dose. Less than 2% of parent drug was recovered in feces. Repaglinide appears to be a substrate for active hepatic uptake transporter (organic anion transporting protein OATP1B1).</p>
<p><span class="Italics">Metformin </span><span class="Italics">HCl</span>: Intravenous single-dose studies in normal subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) or biliary excretion. Renal clearance is approximately 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately 6.2 hours. In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> may be a compartment of distribution. </p>
<p><span class="Underline">Specific Populations</span></p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></p>
<p> PrandiMet </p>
<p>Because PrandiMet contains metformin HCl, it should not be used in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [<span class="Italics">see <a href="#i4i_contraindications_id_762b4592-ea74-4134-b6f9-c6a51d185e23">Contraindications (4)</a></span>; <span class="Italics"><a href="#i4i_section_id_2a30a5f3-e661-46b1-869b-e1f487223b03">Warnings and Precautions (5.2)</a></span>].</p>
<p><span class="Italics">Repaglinide</span></p>
<p>Single-dose and steady-state pharmacokinetics of repaglinide were compared between patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and normal renal function (CrCl &gt; 80 mL/min), mild to moderate renal function impairment (CrCl = 40 - 80 mL/min), and severe renal function impairment (CrCl = 20 - 40 mL/min). Both AUC and C<span class="Sub">max</span> of repaglinide were similar in patients with normal and mild to moderately <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (mean values 56.7 ng/mL*hr vs 57.2 ng/mL*hr and 37.5 ng/mL vs 37.7 ng/mL, respectively). Patients with severely reduced renal function had elevated mean AUC and C<span class="Sub">max</span> values (98.0 ng/mL*hr and 50.7 ng/mL, respectively), but this study showed only a weak correlation between repaglinide levels and creatinine clearance.</p>
<p><span class="Italics">Metformin </span><span class="Italics">HCl</span></p>
<p>In patients with decreased renal function (based on measured creatinine clearance), the plasma and blood half-life of metformin is prolonged and the renal clearance is decreased in proportion to the decrease in creatinine clearance.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></span></p>
<p> PrandiMet </p>
<p>PrandiMet should be avoided in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [<span class="Italics">see <a href="#i4i_section_id_1400adc2-3342-429c-b074-b25eb7e02708">Warnings and Precautions (5.4)</a></span>].</p>
<p><span class="Italics">Repaglinide</span></p>
<p>A single-dose, open-label study was conducted in 12 healthy subjects and 12 patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span> (CLD) classified by Child-Pugh scale and caffeine clearance. Patients with moderate to severe impairment of liver function had higher and more prolonged serum concentrations of both total and unbound repaglinide than healthy subjects (AUC<span class="Sub">healthy</span>: 91.6 ng/mL*hr; AUC<span class="Sub">CLD patients</span>: 368.9 ng/mL*hr; C<span class="Sub">max</span>, <span class="Sub">healthy</span>: 46.7 ng/mL; C<span class="Sub">max</span>, <span class="Sub">CLD patients</span>: 105.4 ng/mL). AUC was statistically correlated with caffeine clearance. No difference in glucose profiles was observed across patient groups. Patients with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span> may be exposed to higher concentrations of repaglinide and its associated metabolites than would patients with normal liver function receiving usual doses. Therefore, repaglinide should generally be avoided in patients with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span>.</p>
<p><span class="Italics">Metformin </span><span class="Italics">HCl</span></p>
<p>No pharmacokinetics studies with metformin HCl have been conducted in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p><span class="Bold"><span class="Italics">Geriatric Patients</span></span></p>
<p>Healthy volunteers treated with repaglinide 2 mg before each of 3 meals, showed no significant differences in repaglinide pharmacokinetics between the group of patients &lt;65 years of age and those ≥65 years of age.</p>
<p>Limited data from controlled pharmacokinetic studies of metformin HCl in healthy elderly subjects suggest that total plasma clearance is decreased, the half-life is prolonged, and C<span class="Sub">max</span> is increased, compared to healthy young subjects. From these data, it appears that the change in metformin pharmacokinetics with aging is primarily accounted for by a change in renal function [<span class="Italics">see <a href="#i4i_section_id_2a30a5f3-e661-46b1-869b-e1f487223b03">Warnings and Precautions (5.2)</a></span>].</p>
<p><span class="Italics"><span class="Underline">Drug Interactions</span></span></p>
<a name="_Refid_d6cb754c-a4ba-49bc-bf33-6f15826da"></a><table>
<caption><span>Table 3: Effect of Other Drugs on AUC and C<span class="Sub">max</span> of Metformin</span></caption>
<col width="33%">
<col width="33%">
<col width="33%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>single and multiple dose co-administration</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule"><p class="First"><span class="Bold">Study Drug</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Metformin AUC</span></p></td>
<td class="Botrule Toprule" align="center"><p class="First"><span class="Bold">Metformin </span><span class="Bold">C<span class="Sub">max</span></span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Cimetidine</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">40% ↑ </p></td>
<td class="Botrule" align="center"><p class="First">60% ↑ </p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Furosemide</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">15% ↑ </p></td>
<td class="Botrule" align="center"><p class="First">22% ↑ </p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Nifedipine</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">9% ↑ </p></td>
<td class="Botrule" align="center"><p class="First">20% ↑ </p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Propranolol-metformin</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">10% ↓ </p></td>
<td class="Botrule" align="center"><p class="First">6% ↓ </p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Ibuprofen-metformin</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">5% ↑ </p></td>
<td class="Botrule" align="center"><p class="First">7% ↑ </p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule" colspan="3">
<p class="First">Unless indicated all drug interactions were observed with single dose co-administration</p>
<p>↑ indicates increase</p>
<p>↓ indicates decrease</p>
</td></tr>
</tbody>
</table>
<a name="_Refid_4d15f591-51b8-472d-a7ba-777894cc7"></a><table>
<caption><span>Table 4: Effect of Other Drugs on AUC and C<span class="Sub">max</span> of Repaglinide</span></caption>
<col width="25%">
<col width="24%">
<col width="17%">
<col width="24%">
<col width="24%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Indicates data are from published literature</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>Two doses, twelve hours apart, healthy volunteers</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">‡</a></dt>
<dd>Single dose of 0.5 mg repaglinide was administered</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">§</a></dt>
<dd>Coadministration of gemfibrozil with PrandiMet is not recommended <span class="Italics">[see <a href="#i4i_section_id_fee49ddf-0ace-4b4e-95cf-eccaa63d3c4b">Warnings and Precautions (5.7)</a></span> and <span class="Italics"><a href="#i4i_section_id_8dda359b-a02f-42e1-9da8-532ad7523efd">Drug Interactions (7.2)</a>]</span>
</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">¶</a></dt>
<dd>Single dose of 2 mg repaglinide was administered</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">#</a></dt>
<dd>2 mg repaglinide was administered TID for 4 days</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">Þ</a></dt>
<dd>Single dose of 4 mg repaglinide was administered</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" rowspan="2"><p class="First"><span class="Bold">Study Drug</span></p></td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2">
<p class="First"><span class="Bold">Dose</span></p>
<p><span class="Bold">Other Drug</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2">
<p class="First"><span class="Bold">Duration Other</span></p>
<p><span class="Bold">Drug</span></p>
</td>
<td class="Botrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Repaglinide</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">AUC</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">C<span class="Sub">max</span></span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Clarithromycin</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">250 mg BID</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4 days</p></td>
<td class="Botrule Rrule" align="center"><p class="First">40% ↑ </p></td>
<td class="Botrule" align="center"><p class="First">67% ↑ </p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Cyclosporine</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">100 mg<a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1 day</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.5 fold ↑</p></td>
<td class="Botrule" align="center"><p class="First">1.8 fold ↑</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Deferasirox</span><a href="#footnote-4" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">30 mg/kg QD<a name="footnote-reference-6" href="#footnote-6" class="Sup">‡</a> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">4 days</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.3 fold ↑</p></td>
<td class="Botrule Lrule" align="center"><p class="First">62% ↑</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Fenofibrate</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">200 mg QD</p></td>
<td class="Botrule Rrule" align="center"><p class="First">5 days</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0%</p></td>
<td class="Botrule" align="center"><p class="First">18% ↑</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Gemfibrozil</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">§</a><a href="#footnote-4" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">600 mg BID</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3 days</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8.1 fold ↑ </p></td>
<td class="Botrule" align="center"><p class="First">2.4 fold ↑ </p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Itraconazole</span><a href="#footnote-4" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">100 mg BID</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3 days</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.4 fold ↑</p></td>
<td class="Botrule" align="center"><p class="First">1.5 fold ↑ </p></td>
</tr>
<tr>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"></td>
</tr>
<tr>
<td class="Botrule Rrule">
<p class="First"><span class="Bold">Gemfibrozil</span><span class="Bold"> + </span><span class="Bold">Itraconazole</span></p>
<p>Co-administration<a href="#footnote-7" class="Sup">§</a><a href="#footnote-4" class="Sup">*</a></p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">Gem: 600 mg BID;</p>
<p>Itra: 100 mg BID</p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">3 days</p></td>
<td class="Botrule Rrule" align="center"><p class="First">19 fold ↑ </p></td>
<td class="Botrule" align="center"><p class="First">2.8 fold ↑ </p></td>
</tr>
<tr>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Ketoconazole</span><a name="footnote-reference-8" href="#footnote-8" class="Sup">¶</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">200 mg QD</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4 days</p></td>
<td class="Botrule Rrule" align="center"><p class="First">15% ↑ </p></td>
<td class="Botrule" align="center"><p class="First">16% ↑ </p></td>
</tr>
<tr>
<td class="Botrule Rrule">
<p class="First"><span class="Bold">Levonorgestrel</span><span class="Bold">/</span><span class="Bold">ethinyl</span></p>
<p><span class="Bold">Estradiol</span><a name="footnote-reference-9" href="#footnote-9" class="Sup">#</a></p>
</td>
<td class="Botrule Rrule" align="center">
<p class="First">(0.15 mg/0.03 mg)</p>
<p>Combination tablet QD</p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">21 days</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.4% ↓ </p></td>
<td class="Botrule" align="center"><p class="First">20% ↑ </p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Nifedipine</span><a href="#footnote-9" class="Sup">#</a><a href="#footnote-4" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">10 mg TID</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4 days</p></td>
<td class="Botrule Rrule" align="center"><p class="First">10% ↓ </p></td>
<td class="Botrule" align="center"><p class="First">5% ↓ </p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Rifampin</span><a name="footnote-reference-10" href="#footnote-10" class="Sup">Þ</a><a href="#footnote-4" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">600 mg QD</p></td>
<td class="Botrule Rrule" align="center"><p class="First">6 - 7 days</p></td>
<td class="Botrule Rrule" align="center"><p class="First">32 - 80% ↓ </p></td>
<td class="Botrule" align="center"><p class="First">17 - 79% ↓ </p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Simvastatin</span><a href="#footnote-9" class="Sup">#</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">20 mg QD</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4 days</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2% ↑ </p></td>
<td class="Botrule" align="center"><p class="First">26% ↑ </p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Trimethoprim</span><a href="#footnote-4" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">160 mg BID</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3 days</p></td>
<td class="Botrule Rrule" align="center"><p class="First">61% ↑ </p></td>
<td class="Botrule" align="center"><p class="First">41% ↑ </p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule" colspan="5">
<p class="First">Unless indicated all drug interactions were observed with single dose of 0.25 mg repaglinide</p>
<p>↑ indicates increase</p>
<p>↓ indicates decrease</p>
</td></tr>
</tbody>
</table>
<a name="_Refid_899a6b65-eb88-43eb-9bb6-475e4098a"></a><table>
<caption><span>Table 5: Effect of Metformin or Repaglinide on AUC and C<span class="Sub">max</span> of Other Drugs</span></caption>
<col width="33%">
<col width="33%">
<col width="33%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-11" href="#footnote-reference-11">*</a></dt>
<dd>When administered with metformin</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">†</a></dt>
<dd>Co-administration of a combination tablet (0.15 mg levonorgestrel/0.03 mg ethinyl estradiol) once daily for 21 days with 2 mg repaglinide administered TID (days 1-4) and a single dose on day 5.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule"><p class="First"><span class="Bold">Other Drugs</span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">AUC</span></p></td>
<td class="Botrule Toprule" align="center"><p class="First"><span class="Bold">C<span class="Sub">max</span></span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Furosemide</span><a name="footnote-reference-11" href="#footnote-11" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">12% ↓ </p></td>
<td class="Botrule" align="center"><p class="First">31% ↓ </p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Ethinyl</span><span class="Bold"> Estradiol</span><a name="footnote-reference-12" href="#footnote-12" class="Sup">†</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">20% ↑ </p></td>
<td class="Botrule" align="center"><p class="First">20% ↑ </p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Fenofibrate</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">0%</p></td>
<td class="Botrule" align="center"><p class="First">18% ↑</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule" colspan="3">
<p class="First">↓ indicates decrease</p>
<p>↑ indicates increase</p>
</td></tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_af696e52-1662-4ba1-9a88-209097db5e50"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_d01a1218-6241-46a6-a446-e15464419da1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Italics">PrandiMet</span></p>
<p>No animal studies have been conducted with the combined products in PrandiMet to evaluate carcinogenesis, mutagenesis and impairment of fertility. The following data are based on findings in studies performed with the individual components.</p>
<p><span class="Italics">Repaglinide</span></p>
<p>In a 104-week carcinogenicity study in rats at doses up to 120 mg/kg/day, the incidences of benign <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> of the thyroid and liver were increased in male rats. The higher incidences of thyroid and <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span> in male rats were not seen at lower dose of 30 mg/kg/day and 60 mg/kg/day respectively (which are over 15 and 30 times, respectively, clinical exposures on a mg/m<span class="Sup">2</span> basis). </p>
<p>In a 104-week carcinogenicity study in mice at doses up to 500 mg/kg/day, no evidence of carcinogenicity was found in mice (which is approximately 125 times clinical exposure on a mg/m<span class="Sup">2</span> basis).</p>
<p>Repaglinide was non-genotoxic in a battery of <span class="Italics">in vivo</span> and <span class="Italics">in vitro</span> studies: Bacterial mutagenesis (Ames test), <span class="Italics">in vitro</span> forward cell mutation assay in V79 cells (HGPRT), <span class="Italics">in vitro</span> chromosomal aberration assay in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, unscheduled and replicating DNA synthesis in rat liver, and <span class="Italics">in vivo</span> mouse and rat micronucleus tests.</p>
<p>In a rat fertility study, repaglinide was administered to male and female rats at doses up to 300 and 80 mg/kg/day, respectively. No adverse effects on fertility were observed (which are over 40 times clinical exposure on a mg/m<span class="Sup">2</span> basis).</p>
<p><span class="Italics">Metformin </span><span class="Italics">HCl</span></p>
<p>In a 104-week carcinogenicity study in rats at doses up to 900 mg/kg/day, the incidences of benign stromal uterine <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> were increased in female rats at 900 mg/kg/day (which is approximately four times the maximal recommended human daily dose of 2000 mg of metformin HCl component of PrandiMet on a mg/m<span class="Sup">2</span> basis).</p>
<p>In a 91-week carcinogenicity study in mice at doses up to 1500 mg/kg/day, no evidence of carcinogenicity was found in mice (which is approximately four times the maximal recommended human daily dose of 2000 mg of metformin HCl component of PrandiMet on a mg/m<span class="Sup">2</span> basis). </p>
<p>There was no evidence of a mutagenic potential of metformin HCl alone in the following <span class="Italics">in vitro</span> tests: Ames test (<span class="Italics">S. </span><span class="Italics">typhimurium</span>), gene mutation test (mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells), or chromosomal aberrations test (human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>). Results in the <span class="Italics">in vivo</span> mouse micronucleus test were also negative.</p>
<p>In a rat fertility study, metformin HCl was administered to male and female rats at doses up to 600 mg/kg/day. No adverse effects on fertility were observed (which is approximately three times the maximal recommended human daily dose of 2000 mg of metformin HCl component of PrandiMet on a mg/m<span class="Sup">2</span> basis). </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_87e4332e-2dff-4277-a5c6-5df5b258b59f"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_26758fd3-abc7-41e3-b4f9-af25403a7831"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Patients with Inadequate Glycemic Control on Metformin HCl Monotherapy</h2>
<p class="First">In a double-blind, clinical trial, 83 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and inadequate glycemic control on metformin HCl monotherapy were randomized to add-on repaglinide, repaglinide monotherapy, or continued treatment with metformin HCl monotherapy. The repaglinide dosage was titrated for 4 to 8 weeks, followed by a 3-month dose maintenance period. Repaglinide add-on to metformin HCl resulted in a statistically significant improvement in HbA<span class="Sub">1c</span> and fasting plasma glucose compared to the monotherapy arms (Table 6). In this study where metformin HCl dosage was kept constant, repaglinide add-on to metformin HCl resulted in a greater reduction in HbA<span class="Sub">1c</span> and fasting plasma glucose at a lower daily repaglinide dosage than in the repaglinide monotherapy group (dose sparing with respect to repaglinide). However, the repaglinide add-on to metformin HCl group had a higher incidence of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> than the repaglinide monotherapy group [see <span class="Italics"><a href="#i4i_section_id_f823c055-eded-46a8-a402-69f2d5ffeff4">Adverse Reactions (6.2)</a></span>]. The 2 repaglinide treatment arms experienced <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, whereas the metformin HCl monotherapy arm had <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>. </p>
<a name="_Refid_bea994a9-dbef-414b-b256-596a2652c"></a><table>
<caption><span>Table 6. Repaglinide as Add-on to Metformin HCl: Mean Changes from Baseline in Glycemic Parameters and Body Weight After 4 to 5 Months of Treatment<a name="footnote-reference-13" href="#footnote-13" class="Sup">*</a></span></caption>
<col width="28%">
<col width="28%">
<col width="20%">
<col width="23%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-13" href="#footnote-reference-13">*</a></dt>
<dd>based on intent-to-treat analysis</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">†</a></dt>
<dd>p &lt; 0.05, for pairwise comparisons with repaglinide and metformin HCl monotherapy.</dd>
<dt><a name="footnote-15" href="#footnote-reference-15">‡</a></dt>
<dd>p &lt; 0.05, for pairwise comparison with metformin HCl monotherapy.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule"></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">Repaglinide add-on to Metformin HCl</p></td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First">Repaglinide</p>
<p>monotherapy</p>
</td>
<td class="Botrule Toprule" align="center">
<p class="First">Metformin HCl</p>
<p>monotherapy</p>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">N</p></td>
<td class="Botrule Rrule" align="center"><p class="First">27</p></td>
<td class="Botrule Rrule" align="center"><p class="First">28</p></td>
<td class="Botrule" align="center"><p class="First">27</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Median Final Dose (mg/day)</p></td>
<td class="Botrule Rrule" align="center">
<p class="First">6 (repaglinide)</p>
<p>1500 (metformin HCl)</p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">12</p></td>
<td class="Botrule" align="center"><p class="First">1500</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">HbA<span class="Sub">1c</span> (%)</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Baseline</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8.3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8.6</p></td>
<td class="Botrule" align="center"><p class="First">8.6</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Change from baseline</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-1.4<a name="footnote-reference-14" href="#footnote-14" class="Sup">†</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">-0.4</p></td>
<td class="Botrule" align="center"><p class="First">-0.3</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Fasting plasma glucose (mg/</span><span class="Bold">dL</span><span class="Bold">)</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Baseline</p></td>
<td class="Botrule Rrule" align="center"><p class="First">184</p></td>
<td class="Botrule Rrule" align="center"><p class="First">174</p></td>
<td class="Botrule" align="center"><p class="First">194</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Change from baseline</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-39<a href="#footnote-14" class="Sup">†</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">+9</p></td>
<td class="Botrule" align="center"><p class="First">-5</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Weight (kg)</span></p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Baseline</p></td>
<td class="Botrule Rrule" align="center"><p class="First">93</p></td>
<td class="Botrule Rrule" align="center"><p class="First">87</p></td>
<td class="Botrule" align="center"><p class="First">91</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule"><p class="First">Change from baseline</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.4<a name="footnote-reference-15" href="#footnote-15" class="Sup">‡</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">3.0</p></td>
<td class="Botrule" align="center"><p class="First">-0.9</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_b5ff1244-01e5-4681-ab4a-72cd85fba08e"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">PrandiMet tablets are supplied as biconvex tablets available in 1 mg/500 mg (yellow) and 2 mg/500 mg (pink) strengths. Tablets are debossed with the Novo Nordisk (Apis) bull symbol on one side and tablet strength on the other side. The tablets are colored to indicate strength.</p>
<table>
<col width="48%">
<col width="46%">
<col width="21%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" rowspan="2"><p class="First">1 mg repaglinide/500 mg metformin HCl tablets (yellow)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"> Bottles of 20</p></td>
<td class="Botrule Toprule" align="center"><p class="First"> NDC 0169-0093-21</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">Bottles of 100</p></td>
<td class="Botrule" align="center"><p class="First">NDC 0169-0093-01</p></td>
</tr>
<tr>
<td class="Botrule Rrule" rowspan="3"><p class="First">2 mg repaglinide/500 mg metformin HCl tablets (pink)</p></td>
<td class="Botrule Rrule" align="center"><p class="First"> Bottles of 20</p></td>
<td class="Botrule" align="center"><p class="First"> NDC 0169-0092-21</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="center"><p class="First">Bottles of 100</p></td>
<td class="Botrule" align="center"><p class="First">NDC 0169-0092-01</p></td>
</tr>
</tbody>
</table>
<p>Do not store above 25° C (77° F).</p>
<p>Protect from moisture. Keep bottles tightly closed.</p>
<p>Dispense in tight containers with safety closures.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_71b5f799-bcad-4fb5-abd2-22bd8ba9995c"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f21acd02-d5f3-42c4-8f6a-865fe2cc2680"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Physician Instructions</h2>
<p class="First">Patients should be informed of the potential risks and advantages of PrandiMet and of alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of blood glucose, HbA<span class="Sub">1c</span>, renal function, and hematologic parameters. The risks of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, its symptoms and treatment, and conditions that predispose to its development and concomitant administration of other glucose-lowering drugs should be explained to patients and family members. Medication requirements may change during periods of stress such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, or surgery, due to loss of glycemic control. Patients should be advised to seek medical advice promptly.</p>
<p>The risks of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, its symptoms, and conditions that predispose to its development, as noted in the <span class="Italics"><a href="#i4i_section_id_14e0b124-f6b0-4755-b467-9dff94d37911">Warnings and Precautions (5.1)</a></span>, should be explained to patients. Patients should be advised to discontinue PrandiMet immediately and to promptly notify their health practitioner if unexplained <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, unusual <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, or other nonspecific symptoms occur. Once a patient is stabilized on any dose level of PrandiMet, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>, which are common during initiation of metformin HCl therapy, are unlikely to be drug related. Later occurrence of <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> could be due to <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or other serious disease.</p>
<p>Patients should be instructed to take PrandiMet with meals. Doses are usually taken within 15 minutes prior to the meal but the timing can vary from immediately preceding the meal up to 30 minutes before the meal. Patients who skip a meal should be instructed to skip the PrandiMet dose for that meal.</p>
<p>Patients should be counseled against excessive alcohol intake, either acute or chronic, while receiving PrandiMet. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_15d8d790-f501-4e3b-b8c5-86fa75a73969"></a><a name="section-15.2"></a><p></p>
<h2>17.2 Laboratory Tests</h2>
<p class="First">Initial and periodic monitoring of hematologic parameters (e.g., hemoglobin/hematocrit and red blood cell indices) and renal function (serum creatinine) should be performed, at least on an annual basis. Vitamin B<span class="Sub">12</span> deficiency should be excluded if <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span> is detected.</p>
<p>Version: 5</p>
<p><span class="Italics">PrandiMet</span><span class="Italics"><span class="Sup">®</span> is a registered trademark of Novo Nordisk A/S.</span></p>
<p>© 2008 - 2012 Novo Nordisk </p>
<p>US Patent No. 6,677,358</p>
<p>Manufactured for:</p>
<p>Novo Nordisk A/S</p>
<p>DK-2880 Bagsvaerd, Denmark</p>
<p>For information contact:</p>
<p>Novo Nordisk Inc.</p>
<p>100 College Road West </p>
<p>Princeton, New Jersey 08540</p>
<p>1-800-727-6500</p>
<p>www.novonordisk-us.com</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_49053441-6399-4f7d-9b5f-2f26394d5718"></a><a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">1 mg/500 mg Tablets</p>
<p><span class="Bold">PrandiMet</span></p>
<p><span class="Bold">(</span><span class="Bold">repaglinide</span><span class="Bold">/</span><span class="Bold">metformin  </span><span class="Bold">HCl</span><span class="Bold">) Tablets</span></p>
<p><span class="Bold">1 mg/500 mg</span></p>
<p>NDC 0169-0093-01</p>
<p>List 009301</p>
<p>100 Tablets</p>
<p>Rx Only</p>
<div class="Figure">
<a name="id1660"></a><img alt="Carton Display Panel - 1 mg/500 mg Tablets " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5be33711-b77d-4a01-87c8-3b2618c16e8f&amp;name=ad18920e-7672-4fba-841a-6607835064d2-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_a007f2aa-bbd2-4591-a030-6daa90048a0e"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">2 mg/500 mg Tablets</p>
<p><span class="Bold">PrandiMet</span></p>
<p><span class="Bold">(</span><span class="Bold">repaglinide</span><span class="Bold">/</span><span class="Bold">metformin  </span><span class="Bold">HCl</span><span class="Bold">) Tablets</span></p>
<p><span class="Bold">2 mg/500 mg</span></p>
<p>NDC 0169-0092-01</p>
<p>List 009201</p>
<p>100 Tablets</p>
<p>Rx Only</p>
<div class="Figure">
<a name="id1684"></a><img alt="Carton Display Panel - 2 mg/500 mg Tablets" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5be33711-b77d-4a01-87c8-3b2618c16e8f&amp;name=ad18920e-7672-4fba-841a-6607835064d2-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PRANDIMET 		
					</strong><br><span class="contentTableReg">repaglinide and metformin hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0169-0093</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>REPAGLINIDE</strong> (REPAGLINIDE) </td>
<td class="formItem">REPAGLINIDE</td>
<td class="formItem">1 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>METFORMIN HYDROCHLORIDE</strong> (METFORMIN) </td>
<td class="formItem">METFORMIN HYDROCHLORIDE</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>IRON</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MEGLUMINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLACRILIN POTASSIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLOXAMER 188</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (BICONVEX) </td>
<td class="formLabel">Size</td>
<td class="formItem">5mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">1mg;500mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0169-0093-90</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">12  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0169-0093-21</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">20  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0169-0093-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022386</td>
<td class="formItem">01/16/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PRANDIMET 		
					</strong><br><span class="contentTableReg">repaglinide and metformin hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0169-0092</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>REPAGLINIDE</strong> (REPAGLINIDE) </td>
<td class="formItem">REPAGLINIDE</td>
<td class="formItem">2 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>METFORMIN HYDROCHLORIDE</strong> (METFORMIN) </td>
<td class="formItem">METFORMIN HYDROCHLORIDE</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>IRON</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MEGLUMINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLACRILIN POTASSIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLOXAMER 188</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (BICONVEX) </td>
<td class="formLabel">Size</td>
<td class="formItem">5mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">2mg;500mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0169-0092-90</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">12  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0169-0092-21</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">20  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0169-0092-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022386</td>
<td class="formItem">01/15/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Novo Nordisk
							(622920320)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Recipharm Stockholm AB</td>
<td class="formItem"></td>
<td class="formItem">351517789</td>
<td class="formItem">MANUFACTURE(0169-0093, 0169-0092)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ad18920e-7672-4fba-841a-6607835064d2</div>
<div>Set id: 5be33711-b77d-4a01-87c8-3b2618c16e8f</div>
<div>Version: 7</div>
<div>Effective Time: 20120424</div>
</div>
</div> <div class="DistributorName">Novo Nordisk</div></p>
</body></html>
